Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Low-dose diclofenac potassium in U.K.

This article was originally published in The Tan Sheet

Executive Summary

The Medicines and Healthcare Products Regulatory Agency moves a low dosage of diclofenac potassium, a non-steroidal anti-inflammatory drug, from prescription-only status to pharmacy class. Diclofenac potassium 12.5 mg tablets may be supplied without a prescription - similar to what is called "behind the counter" in the U.S. - to adults and children ages 14 and up to provide short-term relief from headaches, symptoms associated with flu or cold and mild to moderate pain relief, according to a July 8 update by MHRA. Diclofenac potassium is available in the U.S. only in 50 mg prescription products, according to FDA records...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS101869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel